{"nctId":"NCT01631110","briefTitle":"Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains","startDateStruct":{"date":"2012-07"},"conditions":["Influenza"],"count":110,"armGroups":[{"label":"Elderly subjects aged over 60 years","type":"EXPERIMENTAL","interventionNames":["Biological: Inflexal V"]},{"label":"Adults from 18 to 60 years old inclusive","type":"EXPERIMENTAL","interventionNames":["Biological: Inflexal V"]}],"interventions":[{"name":"Inflexal V","otherNames":["Inflexal V influenza vaccine (surface antigen, inactivated, virosome) formulated for the WHO requirements of the 2012-2013 season, each 0.5 mL dose containing:","• 15 µg HA antigen of A/California/7/2009 (H1N1)-like virus","• 15 µg HA antigen of A/Victoria/361/2011 (H3N2)-like virus","• 15 µg HA antigen of B/Wisconsin/1/2010-like virus"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy female and male adults aged ≥18 on Day 1\n* Written informed consent\n* Female subjects of childbearing potential using and willing to continue using an acceptable method of contraception unless surgically sterilized/hysterectomized or post-menopausal for more than 2 years\n\nExclusion Criteria:\n\n* Acute exacerbation of bronchopulmonary infection (cough, sputum, lung findings) or other acute disease\n* Acute febrile illness (≥38.0 °C)\n* Prior vaccination with an influenza vaccine in the past 330 days\n* Known hypersensitivity to any vaccine component\n* Previous history of a serious adverse reaction to influenza vaccine\n* History of egg protein allergy or severe atopy\n* Known blood coagulation disorder\n* Chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of the study vaccine, including oral corticosteroids in dosages of ≥0.5 mg/kg/d prednisolone or equivalent (inhaled or topical steroids are allowed)\n* Known immunodeficiency (incl. leukemia, HIV seropositivity), cancer\n* Investigational medicinal product received in the past 3 months (90 days)\n* Treatment with immunoglobulins or blood transfusion(s) received in the past 3 months (90 days)\n* Pregnancy or lactation\n* Participation in another clinical trial\n* Employee at the investigational site, or relative of the investigator\n* Subjects who in the view of the investigator will not comply with study procedures and/or visit requirements as per protocol","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Seroprotection","description":"Seroprotection rate, defined as proportion of subjects with HI antibody titer ≥1:40 (The primary endpoints are the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters were analyzed according to the EMA \"Note for guidance on harmonisation of requirements for influenza vaccines,\" 1997)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","spread":null},{"groupId":"OG001","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.7","spread":null},{"groupId":"OG001","value":"70.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Local and Systemic Adverse Events, as a Measure of Safety and Tolerability","description":"Solicited local and systemic AEs, Unsolicited AEs\n\nUnsolicited AEs were collected from baseline (Day 1) to 3 weeks after vaccination (Day 22 ± 2 days).\n\nSolicited local and systemic AEs were collected by subjects diary from Day 1 (day of vaccination) to Day 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Seroconversion","description":"Seroconversion rate, defined as proportion of subjects with ≥4-fold increase in HI antibody titer and with a titer of ≥1:40 (The primary endpoints are the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters were analyzed according to the EMA \"Note for guidance on harmonisation of requirements for influenza vaccines,\" 1997)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":null},{"groupId":"OG001","value":"45.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null},{"groupId":"OG001","value":"12.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","spread":null},{"groupId":"OG001","value":"41.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer","description":"GMT of HI antibodies and fold-increase in GMT (The primary endpoints are the immunogenicity parameters for HA assessed via hemagglutinin inhibition method (HI). These parameters were analyzed according to the EMA \"Note for guidance on harmonisation of requirements for influenza vaccines,\" 1997)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.15","spread":null},{"groupId":"OG001","value":"4.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.96","spread":null},{"groupId":"OG001","value":"1.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.40","spread":null},{"groupId":"OG001","value":"3.33","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":55},"commonTop":["Injection site pain","Injection site erythema","Injection site induration","Headache","Injection site haemorrhage"]}}}